Boundless Bio, Inc.

2:00 PM - 2:15 PM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Boundless Bio, a San Diego based company backed by ARCH Venture Partners, City Hill Ventures, Vertex Ventures, Tavistock, GT Healthcare, and Alexandria Venture Investments is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence.

When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.

Targeting ecDNA represents the next revolution in delivering transformative medicines that improve the lives of patients with cancer.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Small molecule directed to novel, undisclosed ecDNA target
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided